Ring Containing Patents (Class 514/559)
-
Publication number: 20110142771Abstract: The photostabilizing electronic excited state energy—particularly singlet state energy from retinoid compounds—has been found to be readily transferred to (accepted by) ?-cyanodiphenylacrylate compounds having an alkoxy radical in the four (para) position (hereinafter “alkoxycrylenes”) on one of the phenyl rings having the formula (I): wherein one of R1 and R2 is a straight or branched chain C1-C30 alkoxy radical, preferably C1-C8, more preferably methoxy, and the non-alkoxy radical R1 or R2 is hydrogen; and R3 is a straight or branched chain C1-C30 alkyl radical, preferably C2-C20. The alkoxycrylene compounds of formula (I) significantly increase the photostability of retinoid compounds in a composition by at least 3-fold and as much as 10-fold or greater. The ability of the alkoxycrylene compounds to stabilize the retinoid compound is concentration dependent, with the amount of retinoid photostabilization increasing with the concentration of the alkoxycrylene compound.Type: ApplicationFiled: February 22, 2011Publication date: June 16, 2011Applicant: HALLSTAR INNOVATIONS CORP.Inventors: Craig A. Bonda, Anna Pavlovic, Jean Zhang
-
Publication number: 20110091387Abstract: The RhoE GTPase pathway has been identified as a target for screening and treatment methods for the prevention and/or reduction of short- and long-term UVB-induced skin damage, e.g., the prevention and/or reduction of UVB-induced wrinkles. The invention thus features screening and treatment methods for prevention or reduction of UVB-induced sin damage, and related compositions, e.g., cosmetic compositions.Type: ApplicationFiled: November 17, 2008Publication date: April 21, 2011Applicants: THE GENERAL HOSPITAL CORPORATION, SHISEIDO CO., LTD.Inventors: Sam W. Lee, Lakshmi Raj, Anna I. Mandinova, Haruhi Iwaki, Yuji Katsuta, Jotaro Nakanishi
-
Publication number: 20110081418Abstract: An object of the present invention is to provide a transdermal absorption enhancer by which various active ingredients are transdermally absorbed. In accordance with a transdermal absorption enhancer of the present invention which effective ingredient is lyotropic liquid crystal which has been utilized as a basic material for pharmaceutical preparations for external application and for cosmetics, transdermal absorption of a macromolecular substance and a water-soluble substance was able to be improved.Type: ApplicationFiled: September 7, 2010Publication date: April 7, 2011Applicants: JAPAN SCIENCE AND TECHNOLOGY AGENCY, NANOEGG RESEARCH LABORATORIES, INC.Inventors: Yoko Yamaguchi, Rie Igarashi
-
Publication number: 20110081410Abstract: The agents of the present invention comprise, as a main ingredient, a polyvalent metal inorganic-salt nanocapsule which encapsulates a retinoid such as retinoic acid. The agents could penetrate into a joint when applied to the skin and induce hyaluronic acid production in a synovial membrane or chondrocyte. Moreover, application of the nanocapsule of the present invention to the skin for a certain period of time lowered the values of inflammatory cytokines and MMPs in the blood.Type: ApplicationFiled: June 23, 2006Publication date: April 7, 2011Applicant: ST. MARIANNA UNIVERSITY, SCHOOL OFMEDICINEInventor: Rie Igarashi
-
Publication number: 20110070224Abstract: A delivery device including at least one stinging capsule and methods of use are described.Type: ApplicationFiled: November 30, 2010Publication date: March 24, 2011Applicant: NanoCyte Inc.Inventors: Tamar LOTAN, Shimon Eckhouse
-
Publication number: 20110064677Abstract: This invention provides new lipoxin analogs, compositions containing analogs, and methods of using these compounds and compositions for treating and preventing oral inflammation, including gingivitis, periodontitis, and other forms of periodontal disease. The invention also provides for methods of treating and preventing oral inflammation, including gingivitis, periodontitis, and other forms of periodontal disease with compositions containing COX-2 inhibitors. Further, the invention provides methods for preventing systemic diseases beyond theoral cavity that are related to periodontal disease using the composition containing lipoxin analogs, COX-2 inhibitors, or both.Type: ApplicationFiled: September 28, 2010Publication date: March 17, 2011Applicants: TRUSTEES OF BOSTON UNIVERSITY, BRIGHAM AND WOMEN'S HOSPITAL, INC., UNIVERSITY OF SOUTHERN CALIFORNIAInventors: Thomas E. Van Dyke, Nicos A. Petasis, Charles N. Serhan
-
Publication number: 20110059117Abstract: A liquid composition suitable for topical use comprising is provided that includes a phospholipid foaming agent and at least one solvent; and a pharmaceutically acceptable active agent; wherein the liquid composition is capable of mechanically foaming without an additional propellant; and wherein upon mechanical foaming of 250 ml of the liquid composition results in a foam with a foam volume of at least about 400 ml and a foam stability wherein at least about 50% of the foam volume is still present after about 5 minutes at 25° C., as determined using a SITA foam measurement. Also provided herein are methods of making disclosed compositions and methods of use.Type: ApplicationFiled: July 19, 2010Publication date: March 10, 2011Inventor: Bernd G. Seigfried
-
Publication number: 20110059159Abstract: Methods for rapidly obtaining a nanoscale apolipoprotein bound phospholipid bilayer (NABB) associated with at least one membrane protein are provided. Also disclosed are methods for rapidly obtaining a NABB not associated with membrane proteins. Immunogenic compositions comprising NABBs with native conformational epitopes are also provided along with their methods of use.Type: ApplicationFiled: January 30, 2009Publication date: March 10, 2011Applicant: THE ROCKEFELLER UNIVERSITYInventors: Thomas P. Sakmar, Thomas Huber, Sourabh Banerjee
-
Publication number: 20110060014Abstract: The use of screening assays based on the role of human stearoyl-CoA desaturase-1 (“hSCD1”) in human diseases, disorders or conditions relating to serum levels of triglyceride, VLDL, HDL, LDL, total cholesterol, or production of secretions from mucous membranes, monounsaturated fatty acids, wax esters, and the like, is disclosed. Also disclosed are conventions useful in the prevention and/or treatment of such diseases.Type: ApplicationFiled: September 9, 2010Publication date: March 10, 2011Inventors: Michael R. Hayden, Alison J. Brownlie, James M. Ntambi, Makoto Miyazaki, Mark P. Gray-Keller, Alan D. Attie
-
Publication number: 20110039930Abstract: The present invention relates to pharmaceutical formulations containing Naproxen and a delivery agent.Type: ApplicationFiled: August 3, 2010Publication date: February 17, 2011Applicant: Emisphere Technologies, Inc.Inventors: Michael Novinski, Patrick Osinski, Nicholas Hart
-
Publication number: 20110038905Abstract: It is an object of the present invention to provide a skin anti-aging agent for external use which comprises highly safe protein nanoparticles having high transparency due to the small particle size and high permeability into skin. The present invention provides a skin anti-aging agent for external use, which comprises protein nanoparticles containing an active ingredient.Type: ApplicationFiled: October 28, 2010Publication date: February 17, 2011Applicant: FUJIFILM CorporationInventors: Makiko AIMI, Kazutaka Ogiwara, Takuo Amano
-
Patent number: 7875744Abstract: The invention features 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs, compositions containing them, and methods of using them as PPAR modulators to treat or inhibit the progression of, for example, dyslipidemia.Type: GrantFiled: August 28, 2009Date of Patent: January 25, 2011Assignee: Janssen Pharmaceutica NVInventors: Gee-Hong Kuo, Rui Zhang, Aihua Wang, Alan DeAngelis, Keith Demarest, Patricia Pelton
-
Publication number: 20110002866Abstract: The described invention relates to delivery of compositions comprising at least one prostaglandin analog to prevent or reduce hair loss (e.g. brittle hair growth, thin hair growth, short hair growth, sparse hair growth) or alopecia associated with chemotherapy.Type: ApplicationFiled: September 14, 2010Publication date: January 6, 2011Inventors: Beverly W. Lubit, Pamela R. Lipkin
-
Publication number: 20110003872Abstract: The present invention relates to a material comprising dendritic molecules each constituted of fragments that are at least bifunctional and of fragments that are at least trifunctional joined together by ester or thioester bridges, alone or in combination with amide or urea bridges, said bridges being formed from two functions carried by different fragments, said molecules containing, on the fragments located at the ends of the dendritic branches, associative end groups capable of forming associations with one another by hydrogen bonds and joined covalently to the functions that are not involved in said bridges. It also relates to the method of production thereof, as well as to its uses and to compositions, notably cosmetic, containing this material.Type: ApplicationFiled: December 2, 2008Publication date: January 6, 2011Applicants: Arkema France, Centre National De La Recherche Scientifique CNRSInventors: François-Genes Tournilhac, Manuel Hidalgo, Ludwik Leibler
-
Publication number: 20100322907Abstract: Described herein are methods, compositions and kits related to manipulating hematopoietic stem cells and more particularly to methods, compositions and kits related to increasing the number of hematopoietic stem cells in vitro and in vivo. Also described are methods, compositions and kits related to making an expanded population of hematopoietic stem cells (HSCs) and methods, compositions and kits related to using the expanded population of HSCs.Type: ApplicationFiled: December 3, 2007Publication date: December 23, 2010Applicant: UNIVERSITY OF ROCHESTERInventors: Laura Maria Calvi, Regis O'Keefe
-
Publication number: 20100317733Abstract: It has now been discovered that inhibitors of soluble epoxide hydrolase (“sEH”) are useful in reducing the severity of or inhibiting the progression of obstructive pulmonary diseases, restrictive airway diseases, and asthma. Administering a cis-epoxyeicosantrienoic acid (“EET”) in addition to the inhibitor is at least additive, and may be synergistic, in reducing or inhibiting these conditions and diseases, as measured by reduced numbers of neutrophils present in the lung. The inhibitor of sEH may be a nucleic acid, such as a small interfering RNA.Type: ApplicationFiled: February 6, 2009Publication date: December 16, 2010Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Bruce D. Hammock, Kent E. Pinkerton, Kevin R. Smith, Takaho Watanabe, Seung Jin Ma
-
Publication number: 20100310680Abstract: This invention relates to a novel composition and method useful for the treatment of acne, and more particularly, to a composition and method for reducing an appearance of post acne marks and scars without skin irritation in a short amount of time.Type: ApplicationFiled: June 9, 2009Publication date: December 9, 2010Inventors: Theresa Chen, Geraldine Watson, I-Ting Wu
-
Patent number: 7838554Abstract: The present invention relates to novel dihydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, metabolic syndrome disorders (e.g., Syndrome X), thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient.Type: GrantFiled: June 9, 2009Date of Patent: November 23, 2010Assignee: Esperion Therapeutics, Inc.Inventors: Jean-Louis Henri Dasseux, Carmen Daniela Oniciu
-
Publication number: 20100285008Abstract: Disclosed are novel methods for the therapeutic treatment of cancer and angiogenesis. The enzyme Ape1/Ref-1, via its redox function, enhances the DNA binding activity of transcription factors that are associated with the progression of cancer. The present invention describes the use of agents to selectively inhibit the redox function of Ape1/Ref-1 and thereby reduce tumor cell growth, survival, migration and metastasis. In addition, Ape1/Ref-1 inhibitory activity is shown to augment the therapeutic effects of other therapeutics and protect normal cells against toxicity. Further, Ape1/Ref-1 inhibition is shown to decrease angiogenesis, for use in the treatment of cancer as well other pathologic conditions of which altered angiogenesis is a component.Type: ApplicationFiled: September 22, 2008Publication date: November 11, 2010Inventor: Mark R. Kelley
-
Publication number: 20100278937Abstract: The present invention relates to methods and materials for killing cancer cells with proteins derived from bacteria. The invention specifically relates to Azurin, Laz, Pa-CARD, and fusion proteins Azu-H.8 and H.8-Azu, and their use in killing leukemia cells and/or ovarian cancer cells.Type: ApplicationFiled: February 22, 2010Publication date: November 4, 2010Inventors: Tapas K. Das Gupta, Ananda Chakrabarty, Arsenio Fialho
-
Publication number: 20100273756Abstract: The present invention is generally directed to the treatment of fine wrinkles, hyperpigmentation, roughness of facial skin, improvement of photoaging, repair of sun damaged skin, and related disorders. In a formulation aspect, the present invention provides a formulation for the adjunct treatment of skin disorders, where the formulation includes tretinoin and azelaic acid. In a method aspect, the present invention provides a method for treating skin disorders. The skin disorders include fine wrinkles, freckles, solar lentigo, skin photodamage, aging process as reflected by changes in a patient's skin, Acne Vulgaris and Melasma or Post-inflammatory hyperpigmentation. The method includes the application of a formulation to a portion of the patient's skin, where the portion exhibits a skin disorder, and wherein the formulation includes tretinoin and azelaic acid.Type: ApplicationFiled: April 23, 2010Publication date: October 28, 2010Inventor: Reza Babapour
-
Publication number: 20100267678Abstract: The present invention is drawn to adhesive solidifying formulations, methods of drug delivery, and solidified layers for dermal delivery of a drug. The formulation can include a drug, a solvent vehicle, and a solidifying agent. The solvent vehicle can include a volatile solvent system comprising at least one volatile solvent, and a non-volatile solvent system comprising at least one non-volatile solvent, wherein at least one non-volatile solvent is a flux-enabling non-volatile solvent(s) capable of facilitating the delivery of the drug at therapeutically effective rates over a sustained period of time. The formulation can have a viscosity suitable for application to a skin surface prior to evaporation of the volatile solvents system. When applied to the skin, the formulation can form a solidified layer after at least a portion of the volatile solvent system is evaporated.Type: ApplicationFiled: April 16, 2010Publication date: October 21, 2010Inventors: Jie Zhang, Kevin S. Warner, Sanjay Sharma
-
Publication number: 20100267640Abstract: The present invention provides a method of attenuating the formation or reducing the severity of neurogenic swelling and/or neurogenic inflammation in the tissue of a patient via applying a composition comprising a hydrophilic foam substrate and a polymeric hydrophilic agent to a portion of the surface of the skin in an amount and at a location sufficient to attenuate formation of or reduce the severity of neurogenic swelling and/or neurogenic inflammation.Type: ApplicationFiled: April 26, 2010Publication date: October 21, 2010Applicant: Sessions Pharmaceuticals, Inc.Inventors: Robert W. Sessions, Alan R. Kahn
-
Publication number: 20100255041Abstract: Disclosed is the use of inhibitors of ?-catenin expression or activity or modulators downregulating ?-catenin expression or activity for the treatment of cardiovascular diseases or disorders and their use in the treatment of cardiovascular diseases and disorders, such as heart failure syndrome. The use of those agents resulted in particular in cardiomyocyte differentiation of endogenous cardiac stem cells.Type: ApplicationFiled: October 5, 2009Publication date: October 7, 2010Applicant: MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZINInventors: Martin BERGMANN, Joerg HUELSKEN, Walter BIRCHMEIER, Makoto Mark TAKETO
-
Patent number: 7807445Abstract: Fermentation of a nutrient medium with a eubacterium Streptomyces sp. yields a novel antibacterial compound of structural formula (I).Type: GrantFiled: May 20, 2005Date of Patent: October 5, 2010Assignees: Merck Sharp and Dohme de Espana, S.A., Merck Sharp & Dohme Corp.Inventors: Angela Basilio, Olga Genilloud, Hiranthi Jayasuriya, Ignacio Gonzalez, Sheo B. Singh, Oscar Salazar, Jun Wang
-
Publication number: 20100210727Abstract: The present invention relates to enantiomeric forms of hepoxilin analogs of Formula I-VIII, pharmaceutical compositions thereof, a method for the separation of said enantiomeric forms of hepoxilin analogs comprising applying said hepoxilin to a chiral phase HPLC column and eluting said hepoxilin with an alkane and alcohol solvent mixture. Said enantiomeric forms of hepoxilin analogs of Formula I-VIII were found to be useful in controlling the biological effects of PPAR mediated transcriptional control for the treatment of diseases such as cancer, thromboxane-mediated diseases and for modulating intracellular calcium concentration.Type: ApplicationFiled: April 19, 2007Publication date: August 19, 2010Applicant: EVOLVA S.A.Inventors: Cecil Pace-Asciak, Alexandra SantAna Sorensen, Jean-Philippe Meyer, Peter Demin
-
Publication number: 20100204327Abstract: Described herein are methods for making retinoids. Also described herein are retinoids and methods of use thereof.Type: ApplicationFiled: August 23, 2005Publication date: August 12, 2010Inventors: Wayne J. Brouillette, Donal D. Muccio, Venkatram Reddy Atigadda, John M. Ruppert, Susan M. Lobo Ruppert
-
Patent number: 7772195Abstract: A method for the treatment of obesity, diabetes, high cholesterol and related diseases including hyperglycemia, lipid disorders, hyperglyceridemia, dyslipidemia and atherosclerosis in mammals using anthocyanins, anthocyanidins, ursolic acid and/or betulinic acid is described. Compositions adapted for these treatments are also described.Type: GrantFiled: March 4, 2005Date of Patent: August 10, 2010Assignee: Board of Trustees of Michigan State UniversityInventors: Muraleedharan G. Nair, Bolleddula Jayaprakasam, Lawrence K. Olson, Robert E. Schutzki
-
Publication number: 20100196454Abstract: Provided herein is a scar dressing formulation comprising a blend of a high molecular weight silicone elastomer crosspolymer and a silicone oil, wherein said silicone elastomer crosspolymer is in a volatile fluid. The formulation has a soft, silky feel without being greasy and dries quickly to form a durable, flexible scar dressing.Type: ApplicationFiled: September 8, 2009Publication date: August 5, 2010Inventor: Brian KELLER
-
Patent number: 7763282Abstract: The present invention describes a quaternary composition consisting of propolis delivered in a hydrophilic carrier (cyclodextrin and cyclodextrin derivatives) and co ground with the aid of two compounds for the preparation thereof in the form of a finely divided powder. The composition exhibits advantageous dissolution characteristics in aqueous environments compared to native propolis, hence resulting in greater bioavailability of the active ingredients contained therein.Type: GrantFiled: December 2, 2003Date of Patent: July 27, 2010Assignee: Actimex S.R.L.Inventors: Paolo Corvi Mora, Fabio Carli, Tiziana Canal
-
Publication number: 20100184714Abstract: A composition comprises a mixture of a silicone and a first solvent, a drug, such as a hydrophilic or lipophilic pharmaceutical agent, a salt of a dialkyl sulfosuccinate, such as dioctyl sodium sulfosuccinate (DOSS), and a second solvent, such as an alcohol. The salt of a dialkyl sulfosuccinate solubilizes the drug. The composition can be topically applied to a substrate, such as skin, for delivering the drug. Drugs with a wide solubility range are soluble and compatible in the composition without separation or crystallization of the drugs occurring.Type: ApplicationFiled: July 11, 2008Publication date: July 22, 2010Inventors: Victor Albert Raul, Linda Sue Nartker
-
Patent number: 7750042Abstract: One embodiment of the present invention is a compound represented by the Structural Formula (I): Y is a covalent bond of a substituted or unsubstituted straight chained hydrocarbyl group. In addition, Y, taken together with both >C?Z groups to which it is bonded, is a substituted or unsubstituted aromatic group. Preferably, Y is a covalent bond or —C(R7R8)—. R1 is an aliphatic group, a substituted aliphatic group, a non-aromatic heterocyclic group, or a substituted non-aromatic heterocyclic group, R2-R4 are independently —H, an aliphatic group, a substituted aliphatic group, a non-aromatic heterocyclic group, a substituted non-aromatic heterocyclic group, an aryl group or a substituted aryl group, or R1 and R3 taken together with the carbon and nitrogen atoms to which they are bonded, and/or R2 and R4 taken together with the carbon and nitrogen atoms to which they are bonded, form a non-aromatic heterocyclic ring optionally fused to an aromatic ring.Type: GrantFiled: March 20, 2008Date of Patent: July 6, 2010Assignee: Synta Pharmaceuticals Corp.Inventors: Keizo Koya, Lijun Sun, Shoujun Chen, Noriaki Tatsuta, Yaming Wu, Mitsunori Ono, Zhi-Qiang Xia
-
Publication number: 20100166886Abstract: The invention features a method of (i) reducing the appearance of pores or oil on the skin and (ii) evening skin tone or smoothing skin by applying to an area of skin in need of such treatment a composition including an anti-acne agent, an antimicrobial agent, and a lactate.Type: ApplicationFiled: March 12, 2010Publication date: July 1, 2010Inventors: Jeffrey M. Wu, Jue-Chen Liu, Jeannette Chantalat, Ying Sun, Stefanie A. Johnsen, Hanuman B. Jampani
-
Publication number: 20100151035Abstract: The present invention relates to a stable pharmaceutical composition of a poorly water-soluble drug with a view to increasing its solubility and bioavailability. The present invention relates to a solid dispersion of a poorly water-soluble drug.Type: ApplicationFiled: March 10, 2008Publication date: June 17, 2010Applicant: Sandoz AGInventors: Bharatrajan Ramaswami, Manisha Rajesh Patil, Aditi Das
-
Publication number: 20100136108Abstract: A new pharmaceutical formulation for retinoid-containing soft gelatin capsules is disclosed. The new formulation comprises a soft gelatin capsule filled with a fill mass comprising a retinoid as an active ingredient, a natural vegetable oil, a partially hydrogenated natural vegetable oil and medium chain triglycerides. Optionally, the new formulation also comprises a natural wax. In a particularly preferred embodiment, the soft gelatin capsule comprises pig gelatin in the capsule shell in combination with the above fill mass.Type: ApplicationFiled: December 17, 2009Publication date: June 3, 2010Inventors: Günter Ditzinger, Bernhard Gabriel, Anne-Hortense Schmitt-Hoffmann, Lutz Wevelsiep
-
Publication number: 20100125057Abstract: A cream base for the topical application of skin care therapeutics and a process for making the cream base. In one embodiment, the therapeutic is tretinoin, hydroquinone and fluocinolone acetonide for the treatment of hyperpigmented skin conditions, such as melasma.Type: ApplicationFiled: January 22, 2010Publication date: May 20, 2010Applicant: GALDERMA S.A.Inventors: Nancy Puglia, Jerry Roth, Rosario Ramirez
-
Publication number: 20100120768Abstract: The invention features methods, kits, and compositions for generating new hair follicles and growing hair on a subject.Type: ApplicationFiled: September 27, 2007Publication date: May 13, 2010Inventors: David Steinberg, Kevin Pojasek, Stephen Prouty, George Cotsarelis, Mayumi Ito
-
Patent number: 7714024Abstract: Membrane transporter-targeted therapeutic agents and methods of making and using the same.Type: GrantFiled: September 15, 2006Date of Patent: May 11, 2010Assignee: Allergan, Inc.Inventors: Patrick M. Hughes, Orest Olejnik, Joan-En Chang-Lin
-
Publication number: 20100113596Abstract: Transforming growth factor-beta1 (TGF-?1) mediates expression of collagen 1A2 (Col 1A2) gene via a synergistic cooperation between Smad2/Smad3 and Sp1, both act on the Col 1A2 gene promoter. The present invention discloses a method for inhibiting liver fibrosis via a retinoic acid derivative primarily extracted from the mycelia of Phlellinus linteus. The retinoic acid derivative can antagonize TGF-?-induced liver fibrosis through regulation of ROS and calcium influx, decreasing the promoter activity of Col 1A2, hindering the translocalization of phosphorylated Smad2/3-Smad4 complex from cytosol into nucleus and inhibiting Sp1 binding activity.Type: ApplicationFiled: November 5, 2008Publication date: May 6, 2010Inventor: Kun-Lin Yang
-
Publication number: 20100111874Abstract: The present invention provides methods for detecting and treating cancer. In some embodiments, levels of ISG15 are determined, and topoisomerase I and II inhibitors as well as other DNA-damaging agents plus agents that increase the expression of ISG15 are selected and administered.Type: ApplicationFiled: March 17, 2008Publication date: May 6, 2010Applicant: University of Medicine and Dentistry of New JreseyInventors: Leroy F. Liu, Shyamal Desai, Johnson Yin-Nam Lau
-
Patent number: 7700142Abstract: A cereal bran fortified with an effective amount of select additives such as vitamins, minerals, and essential dietary fats to promote digestive health. The fortified cereal bran can be used as a dietary supplement or as an added ingredient to fortify various food products. The additive used herein is an effective amount of vitamin D, selenium, calcium, magnesium, folic acid and omega 3 fatty acids.Type: GrantFiled: May 16, 2005Date of Patent: April 20, 2010Inventor: Diane Wright Hoffpauer
-
Publication number: 20100087532Abstract: A polypeptide is identified as being functionally included in a signal transduction pathway having a biological effect. Contemplated polypeptides are different from a retinoic acid receptor, a retinoid X receptor, or a cellular retinoic acid binding protein, however bind a retinoid or retinoid metabolite, and binding of the retinoid or retinoid metabolite lead to a modulation of the biological effect. In particularly contemplated methods, a retinoid or retinoid metabolite is administered to a cell or mammal in a concentration effective to modulate the biological effect.Type: ApplicationFiled: September 25, 2009Publication date: April 8, 2010Inventor: Gerhart GRAUPNER
-
Publication number: 20100069491Abstract: N-fatty acid-amino acid conjugates and J2 prostanoid-amino acid conjugates are disclosed along with methods for making such conjugates and methods of using these conjugates in the treatment of conditions that involve dysfunctional lipid metabolism, insulin sensitivity, glucose homeostasis, and/or inflammation.Type: ApplicationFiled: June 5, 2009Publication date: March 18, 2010Applicant: University of MassachusettsInventors: Sumner H. Burstein, Robert B. Zurier
-
Publication number: 20100047357Abstract: The invention relates to a composition for topical application comprising as an active ingredient a peroxide and a retinoid wherein one of said peroxide and retinoid is in the form of first microparticles comprising a solid particulate matter of the active ingredient coated by a metal oxide layer and the other of said peroxide and retinoid is present in an uncoated free form or in a coated form of the active ingredient. The invention further relates to method for treating a surface condition in a subject using said composition, a method for preparing a composition exhibiting improved stability, and a kit comprising: (a) a first composition comprising a peroxide as a first active ingredient; and (b) a second composition comprising a retinoid as a second active ingredient; at least one of said first and said second active ingredient being coated by a metal oxide layer.Type: ApplicationFiled: February 3, 2008Publication date: February 25, 2010Applicant: SOL-GEL TECHNOLOGIES LTD.Inventors: Ofer Toledano, Hanan Sertchook, Natalia Loboda, Haim Bar-Simantov, Leora Shapiro, Raed Abu-Reziq
-
Patent number: 7666905Abstract: Methods and pharmaceutical compositions comprise at least one hepoxilin analog of the formula (I) wherein X and R3 are as defined herein. The methods are directed to treatment of a cancer and for promotion of a apoptosis in a cancer cell.Type: GrantFiled: November 29, 2004Date of Patent: February 23, 2010Inventor: Cecil Pace-Asciak
-
Publication number: 20100041748Abstract: The invention relates to Fatty Acid Acetylated Salicylate Derivatives; compositions comprising an effective amount of a Fatty Acid Acetylated Salicylate Derivative; and methods for treating or preventing an inflammatory disorder comprising the administration of an effective amount of a Fatty Acid Acetylated Salicylate Derivative.Type: ApplicationFiled: July 8, 2009Publication date: February 18, 2010Inventors: Jill C. Milne, Michael R. Jirousek, Jean E. Bemis, Jesse J. Smith
-
Patent number: 7662855Abstract: Compositions for topical application for treating a skin disorder (e.g., acne) include a retinoid, which is solubilized completely in alcohol only with the aid of cosolvents such as esters (e.g., alkyl benzoate, isopropyl palmitate, isopropyl myristate, diisopropyl adipate and their derivatives). This completely solubilized retinoid can be used to formulate an emulsion system or liquid to powder suspension containing a second active, such as an antibiotic (e.g., clindamycin).Type: GrantFiled: November 9, 2004Date of Patent: February 16, 2010Assignee: Imaginative Research Associates, Inc.Inventors: Mohan Vishnupad, Naomi Vishnupad
-
Publication number: 20100029765Abstract: Topical aqueous compositions for the treatment of a skin disorder particularly acne. Topical aqueous composition comprising tretinoin and a hydrophilic cellulose derivative as a gelling agent, wherein the composition has a pH of about 4 to about 6.5 and viscosity of less than about 20,000 cP or provided. The composition also relates to the topical administration of tretinoin in combination with an antibiotic.Type: ApplicationFiled: June 16, 2009Publication date: February 4, 2010Applicant: RANBAXY LABORTORIES LIMITEDInventors: Rahul Gupta, Rajesh Pandurang Giradkar
-
Publication number: 20100022645Abstract: The present invention relates to methods of activate an isoform of protein kinase C (PKC) for the treatment of neurological diseases including Alzheimer's disease and stroke using cyclopropanated or epoxidized derivatives of mono- and polyunsaturated fatty acids. The present invention also relates to methods of reducing neurodegeneration using cyclopropanated or epoxidized derivatives of mono- and polyunsaturated fatty acids.Type: ApplicationFiled: July 28, 2009Publication date: January 28, 2010Applicant: BLANCHETTE ROCKEFELLER NEUROSCIENCES INSTITUTEInventors: Thomas J. Nelson, Daniel L. Alkon
-
Patent number: RE41134Abstract: Staple Stable, aqueous gel vehicles are provided for the topical application to the skin of irritating active ingredients such as retinoids, particularly tretinoin, with slow release of the active ingredient and minimal irritancy to the skin. The vehicles include a gelling agent effective to form a gel and hold the active ingredient in the aqueous medium for slow release on the skin, and an effective amount of an antioxidant to retard decomposition of the active ingredient. The vehicles and formulations are preferably aqueous emulsions which contain a solubilizing agent for the generally non-water soluble active ingredients, as well as usually an emulsifying agent and/or surfactant. Chelating agents, emollients, preservatives and other adjuvants and additives may also be included in the vehicles and formulations.Type: GrantFiled: June 7, 1999Date of Patent: February 16, 2010Assignee: Alyzan, Inc.Inventor: Gail S. Bazzano